TAU makes breakthrough in drug delivery to treat inflammatory bowel disease
To present the pioneering concept, Peer and his team encoded the anti-inflammatory protein interleukin-10 into mRNA and ...
New colorectal cancer prediction test is more than 90% accurate
A new test developed in the UK can accurately predict whether high-risk patients will develop bowel cancer, also known as ...
Science Daily1d
Crohn's Disease News
July 17, 2023 — Chronic inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis, is on the rise worldwide. The benefits of current medications are limited by problematic ...
New bowel cancer test has ‘90% accuracy’ at predicting disease in those at high risk – without invasive procedures
A NEW method for detecting bowel cancer is more than 90 per cent accurate at predicting which higher risk people will develop ...
healthday on MSN3d
Inflammatory Bowel Disease Tied to Higher Risk for Heart Disease
Male patients with inflammatory bowel disease (IBD) face a higher risk for ischemic heart diseases (IHDs), according ...
The American Journal of Managed Care3d
Mirikizumab Demonstrates Superior Maintenance Efficacy in UC Treatment
Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...
gut.bmj5d
Single-cell omics in inflammatory bowel disease: recent insights and future clinical applications
Inflammatory bowel diseases (IBDs), which include ulcerative colitis (UC) and Crohn’s disease (CD), are chronic conditions ...
Ibj.com11d
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...
EurekAlert!3d
Crohn's & Colitis Congress® spotlights key IBD research findings
The Crohn’s & Colitis Foundation and the American Gastroenterological Association (AGA) are excited to host the annual Crohn’s & Colitis Congress®, taking place Feb. 6-8, in San Francisco, CA. This ...
Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years
Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).